Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology issuer developing engineered T cell therapies for autoimmune diseases. Form 8-K reports cover operating and financial results, corporate presentations, material agreements, and clinical or regulatory updates involving rese-cel and the RESET clinical development program.
Proxy materials describe annual meeting voting matters and governance for holders of Cabaletta Bio common stock. The filing record also identifies the company’s registered common stock, capital-structure disclosures, risk-oriented forward-looking statements, and formal material-event reporting tied to its cell-therapy development and manufacturing strategy.
Cabaletta Bio, Inc. is reported as having a significant shareholder group led by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These reporting persons collectively report beneficial ownership of 2,068,491 shares of Cabaletta Bio common stock, representing 1.3% of the class.
The filing states that the reporting persons have no sole voting or dispositive power over these shares, but hold shared voting and shared dispositive power over 2,068,491 shares. The securities are held through entities over which Millennium Management LLC and related managers exercise voting control and investment discretion, and the reporting persons state that this disclosure should not be construed as an admission of beneficial ownership. They also indicate that they now hold 5 percent or less of Cabaletta Bio’s common stock.
Cabaletta Bio, Inc. reported results from its Annual Meeting of Stockholders held on June 9, 2026. Stockholders approved an amendment to the company’s charter to increase authorized common shares from 300,000,000 to 600,000,000, expanding the company’s capacity to issue new equity in the future.
As of April 20, 2026, there were 111,324,796 shares of voting common stock outstanding. Stockholders elected two Class I directors, Scott Brun, M.D. and Shawn Tomasello, MBA, each to serve terms expiring at the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and passed a proposal permitting adjournment of the meeting if needed for additional proxy solicitation in connection with the charter amendment. Proposal 3, a plan amendment proposal, was withdrawn by the board and not voted upon.
Cabaletta Bio director Shawn Tomasello received a grant of stock options covering 22,000 shares of Common Stock. The options have an exercise price of $3.22 per share and are held directly. This is a compensation-related award rather than an open-market purchase or sale.
The option vests in full on the earlier of June 9, 2027 or the date of Cabaletta Bio’s next annual meeting of stockholders, and expires on June 8, 2036. Following this grant, Tomasello holds 22,000 option-derived shares related to this award.
Cabaletta Bio director Simon Mark received a grant of stock options as part of his compensation. The award covers 22,000 options to buy Cabaletta Bio common stock at an exercise price of $3.22 per share, expiring on June 8, 2036.
The options will vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale of shares.
Cabaletta Bio, Inc. director Richard C. Henriques Jr. received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $3.22 per share and expire on June 8, 2036. They will vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting.
Cabaletta Bio director Catherine Bollard received a stock option grant covering 22,000 shares of common stock. The option has an exercise price of $3.22 per share and gives her the right to buy 22,000 shares in the future. It vests in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting, providing equity-based compensation rather than an open-market share purchase.
Cabaletta Bio director Scott C. Brun received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $3.22 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting. Following this award, Brun holds stock options for 22,000 shares. This is a compensation-related grant, not an open-market purchase or sale of shares.
Prudential Financial, Inc. amended its Schedule 13G to report beneficial ownership of 24,267,980 shares of Cabaletta Bio common stock, representing 11.4% of the class as reported. The filing shows shared voting power of 19,465,084 and shared dispositive power of 24,267,980, and identifies Jennison Associates LLC as the subsidiary holding these shares. The amendment is dated 05/31/2026 and was signed on 06/05/2026.
Jennison Associates LLC reports beneficial ownership of 24,267,980 shares (11.4%) of Cabaletta Bio Inc. The filing amends prior disclosures and shows Jennison holds 24,267,980 shares with sole voting power over those shares and shared dispositive power, filed with a reporting date of 05/29/2026 and signed 06/04/2026.
Cabaletta Bio reported new clinical data for its CD19 CAR-T therapy rese-cel across myositis, systemic sclerosis and lupus, alongside development plans toward pivotal trials. In Phase 1/2 RESET-Myositis, 80% of dermatomyositis and antisynthetase patients would have met the planned registrational primary endpoint, with most maintaining immunomodulator‑free responses for up to 1.5 years.
RESET-SSc patients with interstitial lung disease showed a median 7.5% improvement in lung function at 36 weeks and high rCRISS response rates while off immunomodulators. In RESET-SLE, 75% of preconditioned patients with 12‑month follow-up achieved remission by DORIS criteria off immunomodulators, with favorable safety: over 90% of patients across trials had no or only mild cytokine release syndrome and almost all had no ICANS. Cabaletta plans a ~25‑patient SSc registrational study starting 4Q26, topline myositis data in mid‑2027, and a 2H27 BLA including adult and juvenile dermatomyositis.